By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Endo Pharmaceuticals Inc. et al. v. Barr Laboratories Inc.
1:08-cv-00782; filed October 20, 2008 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,662,933 ("Controlled Release Formulation (Albuterol)," issued September 2, 1997) and 5,958,456 (same title, issued September 28, 1999) following a Paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Endo's Opana® ER (oxymorphone hydrochloride, used to treat moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time). View the complaint here.
Ortho-McNeil-Janssen Pharmaceuticals, Inc. et al. v. Watson Laboratories, Inc. et al.
2:08-cv-05103; filed October 16, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,214,815 ("Triphasic Oral Contraceptive," issued April 10, 2001) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Ortho-McNeil's Ortho Tri-Cyclen Lo® (norgestimate and ethinyl estradiol, used for oral contraception). View the complaint here.
Novartis Pharmaceuticals Corp. v. Mylan Pharmaceuticals Inc., et al.
2:08-cv-05042; filed October 10, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 5,354,772 ("Indole Analogs of Mevalonolactone and Derivatives Thereof," issued October 11, 1994) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Novartis' Lescol® (fluvastatin sodium, used to treat hypercholesterolemia). View the complaint here.
Comments